AZTREONAM AS MONO-THERAPY IN INFECTIONS OF URINARY-TRACT WITH SYSTEMIC REPERCUSSION OF PATIENTS WITH RELATIVE CONTRAINDICATION FOR THE USE OF AMINOGLYCOSIDE
Jm. Pedrajas et al., AZTREONAM AS MONO-THERAPY IN INFECTIONS OF URINARY-TRACT WITH SYSTEMIC REPERCUSSION OF PATIENTS WITH RELATIVE CONTRAINDICATION FOR THE USE OF AMINOGLYCOSIDE, Revista Clinica Espanola, 192(6), 1993, pp. 256-259
A comparative study has been performed to evaluate the clinical effica
cy and safety of aztreonam in the treatment of urinary tract infection
s with systemic affectation, in a group of patients who showed a relat
ive contraindication to be treated with aminoglycosides. The group stu
died was formed by 30 patients (21 females and 9 males). Mean age of s
aid group was 78 years and percentage of patients over 65 years was 93
%. Moreover, 53.3% of patients showed nephropathy, 30% diabetes mellit
us and 16.6% hearing disorders. Responsible germ of the infection was
identified through blood and urine culture in 24 patients (80%) being
the most frequent isolated E. Coli (60%). The cure rate was of 76.6% a
nd improvement rate was 13.3%. Three deaths happened on the studied gr
oup (10%). In a patient superinfection due to Enterococcus was detecte
d. There were no significative adverse effects (Hyper-sensibility reac
tions, hematological disorders, nephrotoxicity or hepatotoxicity). Azt
reonam could be an efficacious alternative in the treatment of urinary
infection with systemic affectation, caused by gram negative germs, s
howing low toxicity.